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Antiviral RNAi therapy: emerging approaches
for hitting a moving target
JN Leonard and DV Schaffer
Department of Chemical Engineering and the Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA
The field of directed RNA interference (RNAi) has rapidly
developed into a highly promising approach for specifically
downregulating genes to alleviate disease pathology. This
technology is especially well-suited to treating viral infec-
tions, and numerous examples now illustrate that a wide
range of viruses can be inhibited with RNAi, both in vitro and
in vivo. One principle that has arisen from this work is that
antiviral RNAi therapies must be tailored to the unique life
cycle of each pathogen, including the choice of delivery
vehicle, route of administration, gene(s) targeted and
regulation and duration of RNAi induction. Although effective
strategies will be customized to each virus, all such therapies
must overcome similar challenges. Importantly, treatment
strategies must compensate for the inevitable fact that viral
genome sequences evolve extremely rapidly, and computa-
tional and bioinformatics approaches may aid in the
development of therapies that resist viral escape. Further-
more, all RNAi strategies involve the delivery of nucleic acids
to target cells, and all will therefore benefit from the
development of enhanced gene design and delivery tech-
nologies. Here, we review the substantial progress that has
been made towards identifying effective antiviral RNAi
targets and discuss strategies for translating these findings
into effective clinical therapies.
Gene Therapy (2006) 13, 532–540. doi:10.1038/sj.gt.3302645;
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Introduction
RNA interference (RNAi) is a mechanism for silencing
gene expression that has been conserved through
evolution in eukaryotes ranging from plants to humans.1
In this process, the cellular complex Dicer cleaves a
double-stranded RNA (dsRNA) molecule to yield dou-
ble-stranded duplexes 21–25 nucleotides in length. These
short interfering RNAs (siRNA) then guide the RNAi-
induced silencing complex (RISC) to cleave target
mRNAs that share sequence identity with the siRNA.1–4
Since it was first demonstrated that adding exogenous,
synthetic siRNA molecules to mammalian cells can
induce RNAi,5 there have been rapidly expanding efforts
to develop RNAi therapies that induce the degradation
of target messenger RNA (mRNA) involved in geneti-
cally inherited (i.e. dominant) or acquired disorders. This
review will focus on the features and challenges unique
to applying RNAi towards one important class of
acquired diseases: viral infections.
RNAi is well suited as an antiviral therapy for
numerous reasons. Antiviral therapeutics hinge upon
the ability to discriminate virus from host; however,
viruses rely extensively upon the host cells for many
functions and activities involved in viral replication
and therefore typically offer a very limited number of
therapeutic targets. For example, the majority of anti-
HIV small molecule drugs used in highly active
antiretroviral therapies (HAART), focus on one of two
viral enzymes, reverse transcriptase and protease.6 By
contrast, because RNAi targets a short stretch of viral
nucleic acids rather than a functional domain of a viral
protein, even a small viral genome offers a large number
of potential targets. Furthermore, in principle the
development of RNAi therapeutics can begin once a
viral genome sequence is known, whereas the develop-
ment of small molecule therapies that inhibit complex
protein activities requires the prior elucidation of much
more biological and functional detail. Finally, although
there is limited evidence that RNAi can play a natural
antiviral role in mammalian cells,7–10 it is clear that it
serves as an important defense against viruses in plants
and transposable elements in Caenorhabditis elegans.1,11
Therefore, human viruses may prove a particularly
fruitful therapeutic target for this evolutionarily con-
served mechanism.
Along with these potentially advantageous features,
viruses pose a number of unique challenges for RNAi-
based therapies. Viruses replicate extremely rapidly and
accumulate mutations and short deletions, particularly
viruses with life cycles that involve RNA genomes. As
discussed in further detail below, since RNAi relies upon
nearly perfect sequence identity between an siRNA
guide and the mRNA target, the accumulation of
mutations can render a virus resistant to RNAi suppres-
sion, analogous to the evolution of viral resistance to
HAART.6 Furthermore, during viral replication, dsRNA
encoding viral proteins or the full genome is often
generated, potentially exposing the virus to host cell
RNAi. As a result, it is not surprising that numerous
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viruses have evolved efficient suppressors of RNAi.
Although this phenomenon is better characterized in
plant infections than in animal viruses,1 the apparent
presence of RNAi suppressors in human viruses in-
dicates that they could impact antiviral RNAi strate-
gies.7,8,10,12 For instance, the vaccinia E3L and influenza
NS1 proteins suppress RNAi when expressed in hetero-
logous systems,12 although it is not yet clear whether
this activity was ‘intentionally’ evolved by the virus
or is a side effect of the ability of these proteins to bind
dsRNA. Furthermore, it was recently reported that the
human immunodeficiency virus type 1 (HIV-1) trans-
criptional activator protein (Tat) also suppresses RNAi
by directly inhibiting Dicer.10 Targeting an early stage in
the viral life cycle before a suppressor accumulates,
or directly targeting the suppressor mRNA, may be
necessary to circumvent these mechanisms of viral
resistance.
The delivery challenge
In general, the RNAi-inducing cargo and its delivery
system should be designed to match the life cycle and
pathology of the target virus. The first option is to deliver
synthetic siRNA molecules, either naked or complexed
with a synthetic vector.5,13,14 Alternatively, one can
deliver plasmid or viral vector constructs that induce
cells to transcribe two complementary RNA molecules
that will hybridize to generate an siRNA, or a short
hairpin RNA (shRNA) that folds to yield a Dicer
substrate.13,15,16 Synthetic siRNAs can provide rapid but
transient suppression, which is appropriate for acute
viral infections such as influenza or SARS,14,17–20 whereas
delivery of expression constructs can provide more
sustained RNAi that is suitable for chronic infectious
such as hepatitis or HIV-1.10,16,21–33 Likewise, delivery
should be focused to tissues where the target pathogen
resides and replicates, somewhat analogous to targeting
vaccine delivery to focus immunity in tissues that lie in
the pathogen’s infectious route of entry into an organ-
ism.34 For example, influenza and respiratory syncytial
virus (RSV)35 therapies are most appropriately delivered
by inhalation,18 whereas hepatitis therapy can be
administered intravenously for liver targeting.13,22 Simi-
larly, T cells and macrophages can be protected against
HIV by harvesting and transducing hematopoietic stem
cells with a virus ex vivo to introduce anti-HIV RNAi
constructs.28
In addition, the RNAi-inducing nucleic acids must be
delivered within a therapeutic window of dosage, as
dose-dependence has been observed both in vitro and
in vivo. Lentiviral vector delivery of an shRNA-expres-
sing construct progressively knocked down target gene
expression in single cells with increasing viral dosage.36
Likewise, in a study of intranasal delivery of polyplex
delivery vehicles composed of synthetic anti-influenza
siRNAs and the polycationic polymer polyethylenimine,
higher siRNA doses protected mice challenged with
influenza more effectively.14 Efficient nucleic acid deliv-
ery has been a major challenge in the parallel field of
gene therapy, so all delivery vehicles and routes of
administration for RNAi-inducing cargo will benefit
from prior and continual progress in synthetic and viral
vector development.37
In addition to a lower delivery limit for efficacy,
several phenomena restrict the maximal dosage of RNAi
that a host can tolerate. Long dsRNAs, the natural
substrates that Dicer processes to generate siRNAs, are
known to activate protein kinase R and thereby induce
interferon expression, whereas siRNAs themselves are
not typically associated with an innate immune response.
However, high dosages of synthetic siRNA delivery can
stimulate cytotoxic interferon and inflammatory cytokine
secretion in a sequence-dependent fashion.38 In addition,
while siRNAs target degradation of mRNAs with a high
degree of sequence specificity, they can in some cases
also eliminate mRNA containing similar sequences,
leading to broader, unintended modulation of host gene
expression.39,40 These nonspecific or off-target effects
lead to the possibility of clinical side effects. Further-
more, shRNAs interact with another endogenous cellular
pathway for suppression of gene expression, the micro-
RNA (miRNA) system. miRNAs are initially transcribed
as partially double-stranded precursors and are subse-
quently processed by the RNase III enzyme Drosha to
yield RNA hairpins. These hairpins are then exported
from the nucleus by Exportin 5 and subsequently
suppress the cytoplasmic translation of target mRNAs.
Exogenous shRNAs expressed in the nucleus after
therapeutic gene delivery also undergo Exportin 5-
dependent nuclear export, which can saturate this
transport mechanism.41 A recent report demonstrated
that high-efficiency delivery of certain antihepatitis
shRNA expression constructs to the murine liver using
vectors based on adeno-associated virus serotype 8 could
induce significant liver toxicity, likely through competi-
tive inhibition of endogenous miRNA mechanisms.42
Finally, the RNAi pathway consumes significant
amounts of ATP, so constitutive expression of siRNA or
shRNA constructs could metabolically tax host cells.43
One approach to overcome such side effects is to limit
RNAi to those cells infected with the viral pathogen. The
creation of shRNA expression constructs driven by RNA
polymerase II promoters 44 has enabled the development
of regulated promoters activated by viral infection. For
example, in a recent study an antihepatitis C virus (HCV)
siRNA construct was inserted in front of the HIV LTR
promoter, which contains two NF-kB response elements
and is thereby activated by HCV infection. The delivery
of this construct to HepG2 cells transfected with full-
length hepatitis C virus cDNA significantly silenced viral
gene expression.24 Similarly, Unwalla et al.30 described a
Tat-inducible vector that conditionally expresses anti-
HIV shRNA only when HIV is present, thereby inhibiting
HIV via a negative feedback mechanism. Alternatively,
synthetic siRNA can be administered only upon viral
infection, and the development of targeted delivery
systems may enable specific delivery to affected cell
types.45
Despite the challenges, a large and growing body of
work demonstrates the far-reaching promise of antiviral
RNAi once these obstacles can be fully overcome.
Viral target choice
RNAi has been used to inhibit the expression and block
the replication of a broad range of viral species from
many families of human and mammalian pathogens
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Table 1 Viruses inhibited with RNAi
Virus Family Genome RNAi target Typea System (cell line/other) RNAi
inducerb
References
EBV Herpesviridae dsDNA Zta v NA, 293 shRNA (p) 46
FMDV Picornoviridae RNA (+) VP1 v bhk-21, suckling mice shRNA (p) 47
FMDV Picornoviridae RNA (+) 3P, 3D v bhk-21 siRNA 48
HBV Hepadnaviridae dsDNAc HBsAg v HepG2.2.15, mice siRNA 21
HBV Hepadnaviridae dsDNAc core, Pol, S1, X v HuH-7, mice shRNA (p) 22
HBV Hepadnaviridae dsDNAc X, S v HuH-7, mice shRNA (p) 23
HCV Flaviviridae RNA (+) NS3, NS5B v HuH-7 siRNA 49
HCV Flaviviridae RNA (+) 5’ NTR, core v HuH-7 siRNA 50
HCV Flaviviridae RNA (+) C v HepG2 shRNA
(sv40)
24
HCV Flaviviridae RNA (+) NS5B v HuH-7 siRNA 51
HCV Flaviviridae RNA (+) La, PTB, hVAP-33 c HuH-7 shRNA (p,
ad)
75
HIV Retroviridae RNA (+) CXCR4, CCR5 CD4 c Magi-CXCR4+,-CCR5+, PBMCs shRNA (p) 69
HIV Retroviridae RNA (+) Rev v CD34+ HSC, scid mice shRNA (l) 16
HIV Retroviridae RNA (+) Gag v Jurkat, CEM-SS, HeLa-CD4+ shRNA (p) 10
HIV Retroviridae RNA (+) Tat, Rev v H9 shRNA (aav) 27
HIV Retroviridae RNA (+) CycT1, CDK9 c HeLa siRNA 72
HIV Retroviridae RNA (+) Nef v SupT1 shRNA (r) 29
HIV Retroviridae RNA (+) LTR-TAR, Vir, Nef v HeLa-CD4+, PBL siRNA (p) 25
HIV Retroviridae RNA (+) CXCR4 c HeLa-CD4+/CXCR4+ siRNA 68
HIV Retroviridae RNA (+) PARP-1 c HeLa, J111 siRNA 71
HIV Retroviridae RNA (+) Arp2 c 293 shRNA (p) 32
HIV Retroviridae RNA (+) Tat,Rev v 293/EcR siRNA (p) 26
HIV Retroviridae RNA (+) Tat, Rev v PBMCs, CD34+ monocytes shRNA (l) 28
HIV Retroviridae RNA (+) CXCR4, CCR5 c U87-CD4-CXCR4, -CCR5 siRNA 67
HIV Retroviridae RNA (+) Sam68 c 293T, HeLa shRNA (p) 33
HIV Retroviridae RNA (+) CD4, Gag c, v Magi-CCR5, HeLa-CD4, H9,
ACH-2, PBL
siRNA 52
HIV Retroviridae RNA (+) Rev v 293/EcR, CEM, CD34+ HSC shRNA (p, l) 30
HIV Retroviridae RNA (+) Nef v SupT1 shRNA (r) 31
HIV Retroviridae RNA (+) hRIP c HeLa, HL2/3, Jurkat, primary
macrophages
siRNA 73
HTLV Retroviridae RNA (+) TORC3 c 293T siRNA 74
HPV Papovaviridae dsDNA E6 v HeLa, SiHa, MCF-7, MeWo,
H1299
siRNA,
shRNA (p)
54
HPV Papovaviridae dsDNA E6, E7 v HeLa siRNA 53
IVA Orthomyxoviridae RNA () NP, PA v MDCK, Vero, chicken embryos siRNA 17
IVA Orthomyxoviridae RNA () NP, PA, PB1 v MDCK, Vero, mice siRNA,
shRNA (p, l)
14
IVA Orthomyxoviridae RNA () M2 splice junction v 293T, BHK shRNA (p) 55
IVA Orthomyxoviridae RNA () NP, PA v MDCK, mice siRNA 18
Marburg Filoviridae RNA () NP, VP35 and VP30 v Vero, HeLa-CCL-2 siRNA 56
PIV Paramyxoviridae RNA () F, HN, RdRP v A549 siRNA 57
PIV Paramyxoviridae RNA () P v mice siRNA 35
Poliovirus Picornoviridae RNA (+) capsid, P3 v HeLa S3, mouse embryonic
fibroblasts
siRNA 58
Poliovirus Picornoviridae RNA (+) capsid, P3 v HeLa S3, P19 siRNA,
esiRNA
59
Rotavirus Reoviridae dsRNA VP4, VP7 v MA104 siRNA 61
Rotavirus Reoviridae dsRNA VP4 v MA104 siRNA 60
RSV Paramyxoviridae RNA () P, F, SH v A549 siRNA 57
RSV Paramyxoviridae RNA () P, F v A549 siRNA 62
RSV Paramyxoviridae RNA () P v A549, mice siRNA 35
SARS-CoV Coronaviridae RNA (+) Rep 1A v FRhk-4 siRNA 19
SARS-CoV Coronaviridae RNA (+) Leader v 293T, Vero E6 siRNA,
shRNA (p)
63
SARS-CoV Coronaviridae RNA (+) N v Vero E6 shRNA (p) 64
SARS-CoV Coronaviridae RNA (+) 48 genomic & coding v FRhk-4 siRNA 20
VSV Rhabdoviridae RNA () M, RdRP v HEp-2 siRNA 57
WNV Flaviviridae RNA (+) capsid, NS5 v 293T shRNA (p) 55
av: viral target, c: cellular target.
bEndogenous expression indicated by aav (AAV vector), ad (adenoviral vector), l (lentiviral vector), r (retroviral vector) p (plasmid), sv40
(SV40 vector).
cHBV uses pregenomic RNA to template genomic DNA synthesis.
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(summarized in Table 1). However, viruses vary widely
in their basic biology and reproductive mechanisms,
which suggests that unique strategies are needed to
inhibit each particular virus (see Figure 1). As RNAi is
currently understood, RISC-mediated RNA cleavage is
restricted to cytoplasmically located target molecules,
and since all viruses hijack cellular translation machinery
to express their proteins, the targeting of virally encoded
cytoplasmic mRNAs is a common locus at which all
viruses should be susceptible to inhibition. In support of
this assertion, it has been shown that a broad spectrum of
viruses can be inhibited by targeting essential viral
mRNAs. To date, the list of viruses successfully inhibited
in this manner includes Epstein–Barr virus (EBV),46 foot-
and-mouth disease virus (FMDV),47,48 hepatitis B virus
(HBV),21–23 hepatitis C virus (HCV),24,49–51 human im-
munodeficiency virus type 1 (HIV-1),10,16,25–31,52 human
papilloma virus (HPV),53,54 influenza virus A
Figure 1 RNAi target selection must be tailored to the unique life cycle of the virus. HIV (a) and influenza (b) both have single-stranded
RNA genomes, but each is susceptible to RNAi-mediated blocks at different points in its life cycle. This figure highlights viral and cellular
targets that have been successfully utilized against HIV and influenza and indicates the steps of the viral replication cycles at which such
blocks would occur. However, it is not intended to exhaustively depict all potential targets. Cellular targets appear in blue text, and viral
targets appear in red.
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(IVA),14,17,18,55, Marburg virus,56 human parainfluenza
virus (PIV),35,57 poliovirus,58,59 rotavirus,60,61 RSV,35,57,62
severe acute respiratory syndrome – associated corona-
virus (SARS-CoV),19,20,63,64 vesicular stomatitis virus
(VSV),57 and West Nile virus (WNV).55 In most of these
cases, inhibition was achieved by directly reducing the
viruses’ ability to reproduce. However, Butz et al.54
demonstrated that HPV pathogenesis could be reduced
by targeting the viral inhibitor of apoptosis, E6, to limit
viral spread by selectively inducing apoptosis in
HPV-infected cells. This example also illustrates that
each type of viral infection offers unique treatment
options.
When tailoring an RNAi-based therapy to a particular
virus, the most important consideration is the unique life
cycle of that virus. To a first degree of approximation,
these life cycles can be grouped by the type of nucleic
acids of which the viral genome is composed. For viruses
with DNA genomes, the sole option is to target viral
mRNA. For example, targeting HPV mRNAs was
sufficient to block viral replication and reduce pathogen-
esis.53,54 However, when targeting viruses with positive-
strand RNA genomes (where the viral genomes are
transcribed in the same orientation as the viral mRNAs),
genomic RNA and mRNA might be degraded simulta-
neously due to the fact that they share sequence identity.
Direct cleavage of positive-strand genomic RNA has
been demonstrated for HIV,25 and HBV’s pregenomic
RNA (which serves as both an mRNA and a template for
reverse transcription of genomic DNA) appears to be
similarly susceptible,21–23 but it is not yet clear whether
simultaneous degradation of genomic and mRNA
underlies the observed viral inhibition of the positive-
strand RNA viruses HCV24,49–51 and SARS-CoV.19,20,63,64
The situation appears more complex when targeting
viruses with negative-strand RNA genomes. For exam-
ple, it was shown when applying anti-influenza virus
siRNAs that could potentially induce RNAi against
either sense RNA (mRNA and genome-complementary
RNA made during replication) or antisense RNA
(genomic RNA), only mRNA was susceptible to RISC-
mediated cleavage.17 This selectivity was potentially due
partially to the fact that influenza viral replication takes
place in the nucleus, which isolates and protects viral
RNA from RISC. However, a similar differential suscept-
ibility of viral mRNA and genomic RNA was also
observed when targeting RSV, which has a negative-
strand RNA genome,62 and rotavirus, which has a
dsRNA genome.61 These latter viruses reproduce in
the cytoplasm and should thus be susceptible to RISC;
however, again only viral mRNA was degraded. This
selective vulnerability can be at least partly explained by
the fact that the genomic RNAs of cytoplasmically
replicating viruses are tightly bound by viral proteins
that may protect the RNA from RISC. Moreover, since
effective siRNAs are loaded asymmetrically into RISC,
with a preference for one strand over the other, it is
unlikely that both negative-strand RNA genomes and
viral mRNAs will be targeted simultaneously by a single
siRNA.65 However, synergistic efficacy could be obtained
by targeting the RNA-binding proteins expressed by
cytoplasmically replicating RNA viruses, since such
inhibition could both repress the production of new
viruses and render genomic RNA more susceptible to
RNAi-mediated cleavage. In any case, it is clear that each
unique viral replication mechanism must be taken into
consideration to achieve maximal RNAi-mediated
inhibition.
Viral evolution
One drawback to targeting viral genes with RNAi is that
viral mutation can lead to a loss of sensitivity to RNAi.
This is an especially problematic possibility for the cases
of RNA viruses, which accumulate point mutations up to
107-fold more rapidly than do their counterparts with
DNA genomes.66 In illustration of this problem, RNAi-
resistant mutants arose in cell culture models while
targeting HIV,27,29,31 poliovirus,58,59 HCV51 and HBV.23
Although most of these mutants achieved resistance
through point mutation or deletion of the target
sequence, one HIV mutant escaped RNAi suppression
by accumulating mutations outside of the target se-
quence, thereby creating a new local RNA secondary
structure that presumably excluded RISC.31 These results
demonstrate conclusively that any effective RNAi-based
antiviral therapy must compensate for the evolutionary
potential of the pathogen.
It is possible that the problem of viral evolution can be
circumvented by directing RNAi against essential cellular
cofactors. Ideally, the loss of these cellular targets must
block viral replication without inducing loss of function
pathology in the cells. For example, HIV utilizes the
chemokine receptors CCR5 and CXCR4 as co-receptors
for cell entry, and downregulation of these genes in
immune cells with RNAi blocks HIV infection.67–69
Importantly, humans who are homozygous for deletions
that abolish CCR5 expression have apparently normal
immune function and are naturally more resistant to
HIV.70 In addition, targeting cellular receptors could
truly protect cells from initial viral infection rather than
only impair postinfection viral reproduction, which is
what targeting viral genes achieves. In addition, produ-
cing a block at a viral entry step could strand the virus in
the extracellular space for greater amounts of time,
rendering it more susceptible to immune surveillance
and clearance. Finally, for the virus to compensate for the
loss of its primary receptor and/or coreceptor, it would
need to make a challenging evolutionary leap compar-
able to acquiring novel tissue tropism or crossing a
species barrier.
In addition to cell surface receptors, a number of host
cellular RNAi targets that provide blocks at intracellular
steps have also been identified. For example, the Arp2/3
complex mediates the nucleation step in actin polymer-
ization, and this mechanism is used by some viruses and
bacteria for intracellular transport. HIV infection was
accordingly halted at the step of intracellular trafficking
to the nucleus when cellular Arp2 was inhibited.32
Downregulation of poly(ADP-ribose) polymerase 1
(PARP-1) abolished HIV integration and interfered with
the activation of NF-kB-dependent genes, including the
HIV long terminal repeat (LTR) promoter.71 It is also
possible to impede viral regulatory functions by target-
ing cellular proteins that interact with viral regulatory
factors after the initiation of viral transcription. For
example, HIV gene expression and replication are
critically dependent upon the recruitment of the host
transcriptional complex pTEFb, composed of cyclin T1
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and CDK9, by the viral protein Tat. RNAi targeting
of cyclin T1 and CDK9 was shown to impair
HIV replication.72 In addition, severely attenuated
viral replication was observed when RNAi was
directed against either Sam68 or human Rev-interacting
protein (hRIP), both of which are required for HIV
Rev-mediated nuclear export of unspliced viral genomic
RNA.33,73
Analogous to work with HIV, HTLV’s Tax-mediated
transcriptional activation was blocked by targeting
TORC3, an essential cellular factor recruited to the
viral promoter.74 Furthermore, HCV replication was
reduced by directing RNAi against various cellular
factors, including La, polypyrimidine tract-binding
protein (PTB), and human VAMP-associated protein of
33 kDa (hVAP-33).75 Despite these positive results, a
potential shortcoming of the cellular target approach is
suggested by experiences with HIV-1. In general, viral
replication was more severely crippled by targeting
viral genes than by downregulating cellular genes
alone.76 Moreover, before any such cellular target-
directed inhibition can be applied as a therapy, for
patient safety it must be thoroughly demonstrated that
even a total loss of target gene expression would not be
harmful. Likewise, this approach in particular could
benefit from the further development of strategies to
spatially (in cells and tissues for which a virus has
tropism) and/or temporally (upon viral infection)
regulate RNAi induction.
Another strategy by which viral evolution might be
thwarted is the simultaneous application of multiple
RNAi-inducing species that target several sequences.
This combinatorial strategy is the basis for HAART
treatment for HIV, which has improved patient response
to antiviral drugs by administering a cocktail of several
compounds that targets multiple viral enzymes.77 In fact,
combination RNAi might improve efficacy over single-
target treatment by several mechanisms. First, it has been
shown that a synergistic inhibition of viral replication
was achieved by targeting multiple loci of the same
gene.68 Secondly, by simultaneously targeting several
viral genes and thus blocking multiple steps in the viral
life cycle, enhanced inhibition can also be achieved.20,48
Similarly, simultaneous targeting of multiple cellular
cofactors, such as the HIV receptor and coreceptors, led
to enhanced viral inhibition.69 Finally, to overcome this
more potent inhibition, the virus would have to
accumulate multiple mutations, which significantly
reduces the possibility that a fully resistant mutant will
emerge.51,59,78 An analogous combinatorial approach is
to combine RNAi interference with other gene therapy-
mediated inhibitors of viral replication. For example,
Rossi et al.28 achieved enhanced HIV inhibition by using
a gene therapy vector that simultaneously expressed
siRNA directed against the HIV Rev protein, a nucleolar-
localizing TAR decoy RNA, and a ribozyme that down-
regulates expression of the cellular CCR5 co-receptor.
In fact, RNAi might be combined effectively with any
number of antiviral therapeutics, including dominant-
negative antiviral proteins and more traditional chemo-
therapeutic drugs, such as those currently used in
HAART. Future work will need to synthesize these
principles to identify antiviral strategies that provide
effective and long-term suppression of viral replication
and pathogenesis.
Future directions
It is clear from the abundance of studies in recent years
that many possible strategies and options exist for
blocking viral replication with RNAi. Therefore, as the
field advances towards clinical trials, it is important to
pose a key question: how does one design an optimal
antiviral RNAi-based therapy? In addition to the
extensive empirical data available and the safety, efficacy,
and viral escape considerations described above, it
would be useful to draw upon the growing wealth of
computational and bioinformatics approaches to identify
promising starting points for the empirical testing of
antiviral strategies. Viruses often contain complex gene
regulation circuits that exhibit nonlinear behavior,79 and
targeting specific loci in this circuitry may optimally
suppress viral replication. For example, in analysis of
a bacteriophage T7 model system, Endy et al.80 employed
a computational model to determine that antisense-
mediated therapies should target viral genes involved in
negative-feedback regulation in order to maximize
resistance to viral escape. We recently reported the use
of an agent-based stochastic simulation describing HIV
replication and evolution in the presence of RNAi
directed against the HIV TAR element. This model was
used to identify criteria of siRNA dose, delivery
efficiency, and RNAi target sequence choice (within
TAR) required to maximize the probability of long-term
viral inhibition.78
In the preparation of clinical antiviral RNAi therapies,
it would also be prudent to draw upon the experiences
gained using HAART to manage HIV infections. Clinical
success with HAART can be improved by analyzing
patients’ primary viral isolates to predict viral drug
susceptibility and thereby design drug regimens that
resist treatment failure.77 A direct, although costly,
approach is to perform batteries of in vitro assays to test
viral isolate susceptibility to different therapies. How-
ever, a more cost-effective approach employs statistical
bioinformatics analysis of the viral genotype, that is, the
dominant viral genetic sequences present in a patient’s
isolate.81 For the most part, such approaches use large
data sets to correlate viral genotypes with past histories
of success or failure on specific drug regimens to guide
the choice of optimal drugs. Recent developments have
enhanced the predictive ability of such bioinformatics
methods by explicitly including considerations of viral
evolution. For example, Beerenwinkel et al.82 have
developed a strategy that utilizes the predicted pheno-
types of both the viral isolate and its closest genetic
‘neighbors’. Although such approaches have proven
effective in many cases and at least in the short term,
many patients eventually develop drug-resistant infec-
tions.83 In total, these experiences suggest that computa-
tional tools, in combination with relevant in vitro
experiments and animal models, can improve the
chances for clinical success (and avoid potential pitfalls)
as antiviral RNAi therapies are prepared for human
trials. Importantly, such proactive measures might
preclude the need to amass large databases of clinical
trials before effective solutions can be identified.
In summary, since the first demonstration of RNAi in a
mammalian cello5 years ago,5 there has been enormous
progress towards applying RNAi to antiviral therapy.
Furthermore, clinical applications will benefit from the
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advantages that RNAi-based antiviral therapies hold
over traditional drugs. Since the RNAi mechanism
makes use of an innate cellular pathway, requiring the
introduction of only a dsRNA trigger, it offers the
potential for effective antiviral therapies with minimal
side effects. This consideration is especially relevant
when compared to current treatments for chronic
infections, such as HIV, which consist of chemothera-
peutic drugs that require complicated dosing schedules,
can induce severe side effects that undermine patient
compliance, and can even cause novel medical pro-
blems.84 Moreover, although each antiviral RNAi therapy
will need to target sequences tailored to the particular
virus, the actual therapeutic delivery methods will be
largely similar across many targets. Consequently, it
should be possible to develop new RNAi-based therapies
more rapidly than can be achieved with small molecule
drugs. Such a readily adaptable approach would be
useful in targeting viruses whose dominant genotype
and phenotype vary seasonally, such as influenza,
especially in cases where vaccination is difficult to
predict or in years when the vaccine ineffectively targets
the dominant strains. Similarly, once an effective anti-
viral RNAi-based therapy is developed, it might serve as
a basis for quickly developing treatments for emerging
viral infections, such as Ebola or SARS-CoV. Such
treatments could be made available for treating acute
infections, even before the full biology of such novel
viruses has been elucidated. Finally, RNAi-based thera-
pies might provide a first line of defense against viral
strains that acquire, through natural or human means,
resistance to drugs and vaccines previously found to be
effective. Although much work remains to be carried out
before clinical success is realized, RNAi-based therapies
have emerged as highly promising, modular and
versatile prospects for treating viral infections.
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